×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GLUE – monte rosa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GLUE
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
07:06 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
High
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/16
07:10 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]
12/16
07:00 am
glue
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
Medium
Report
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
12/15
04:15 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]
12/15
04:01 pm
glue
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
High
Report
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
12/11
02:10 pm
glue
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
Low
Report
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
12/11
04:18 am
glue
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
11/30
04:41 am
glue
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Medium
Report
Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/16
07:31 am
glue
Form 8-K Monte Rosa Therapeutics, For: Dec 16
Medium
Report
Form 8-K Monte Rosa Therapeutics, For: Dec 16
11/14
12:20 pm
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/14
09:08 am
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: Avoro Capital Advisors LLC
11/12
04:13 pm
glue
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
Low
Report
Form SCHEDULE 13D/A Monte Rosa Therapeutics, Filed by: Versant Venture Capital VI, L.P.
11/6
07:05 am
glue
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Monte Rosa Therapeutics, For: Sep 30
11/6
07:03 am
glue
Form 8-K Monte Rosa Therapeutics, For: Nov 06
Medium
Report
Form 8-K Monte Rosa Therapeutics, For: Nov 06
10/31
11:04 am
glue
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Monte Rosa Therapeutics, Filed by: VANGUARD GROUP INC
10/17
04:29 pm
glue
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: TCG Crossover GP II, LLC
Low
Report
Form SCHEDULE 13G Monte Rosa Therapeutics, Filed by: TCG Crossover GP II, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: